Hyperbilirubinemia among African American, glucose-6-phosphate dehydrogenase-deficient neonates

Michael Kaplan1, Marguerite Herschel, Cathy Hammerman

  • 1Department of Neonatology, Shaare Zedek Medical Center, PO Box 3525, Jerusalem 91031, Israel. kaplan@cc.huji.ac.il

Pediatrics
|August 3, 2004
PubMed

Insights

African American neonates with glucose-6-phosphate dehydrogenase (G-6-PD) deficiency face a higher risk of hyperbilirubinemia and require more phototherapy. Vigilant monitoring is crucial for these G-6-PD-deficient infants.

Area of Science:

  • Neonatal Medicine
  • Genetics
  • Pediatrics

Background:

  • Glucose-6-phosphate dehydrogenase (G-6-PD) deficiency is common in African Americans.
  • The risk of neonatal hyperbilirubinemia in this population has not been prospectively evaluated.
  • G-6-PD deficiency can lead to hemolytic anemia.

Purpose of the Study:

  • To compare hemolysis and hyperbilirubinemia risk in G-6-PD-deficient African American neonates versus G-6-PD-normal controls.
  • To assess the need for phototherapy in these groups.

Main Methods:

  • Prospective study of healthy, term/near-term male African American neonates.
  • G-6-PD testing via umbilical cord blood.
  • Hemolysis assessed by end-tidal carbon monoxide (ETCOc); bilirubin levels and phototherapy needs monitored.

Main Results:

  • 12.8% of 500 neonates were G-6-PD-deficient.
  • G-6-PD-deficient neonates showed higher ETCOc levels, indicating increased hemolysis.
  • Significantly higher incidence of hyperbilirubinemia (21.9% vs 6.7%) and phototherapy (20.3% vs 5.7%) in G-6-PD-deficient infants.

Conclusions:

  • G-6-PD-deficient African American neonates have increased hemolysis and hyperbilirubinemia risk.
  • These infants require more phototherapy compared to G-6-PD-normal infants.
  • Vigilant monitoring for hyperbilirubinemia is recommended for G-6-PD-deficient newborns.
Abstract

Related Concept Videos

Jaundice01:25

Jaundice

Jaundice, or icterus, is the yellow discoloration of the skin, sclerae, and mucous membranes. It happens when plasma bilirubin levels rise above 2.5-3 mg/dL, leading to bilirubin deposition in tissue.Bilirubin is a byproduct of hemoglobin degradation. In macrophages, hemoglobin breaks down into globin and heme. Globin is converted into amino acids, while heme is turned into biliverdin by heme oxygenase, which is then reduced to unconjugated bilirubin by biliverdin reductase.Unconjugated...
Inborn Errors of Metabolism01:20

Inborn Errors of Metabolism

Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
Glucose Transporters01:27

Glucose Transporters

Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Pathophysiology of Diabetes01:20

Pathophysiology of Diabetes

Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility, suggesting a...
Hyperglycemia01:29

Hyperglycemia

Hyperglycemia is an abnormally high blood glucose level. It is diagnosed by fasting glucose ≥126 mg/dL, 2-hour oral glucose tolerance test (or OGTT) ≥200 mg/dL, random glucose ≥200 mg/dL with symptoms, or HbA1c ≥6.5%. However, HbA1c results may be unreliable in certain conditions, such as anemia or hemoglobinopathies, and the diagnosis should be confirmed unless classic symptoms are present. Postprandial hyperglycemia is typically considered significant when glucose levels exceed 180 mg/dL two...